For decades, biopharma executives have seen operational costs and complexities soar. As commercial pricing, reimbursement, and market access hurdles remain particularly difficult to overcome, CEOs are ...
Bala V Sathyanarayanan serves as EVP & CHRO at Greif, Inc (NYSE: GEF) & Chairman of the Board of Directors at Balmer Lawrie - Van Leer Ltd. Organizations face unprecedented opportunities and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results